anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: Pulmonary arterial hypertension (PAH) represents an important vascular complication of mixed connective tissue disease (MCTD) and systemic sclerosis (SSc). Microvascular involvement in these diseases can be investigated by means of nailfold capillaroscopy (NFC). Microvascular involvement detected in the nailfold bed is the mirror of the microvascular damage occurring in the entire body, further indicating the involvement of the target organs. The aim of this study was to evaluate the microvascular involvement in MCTD patients with or without PAH, compared to that found in SSc patients with or without PAH.
PATIENTS AND METHODS: This cross-sectional study was performed in the Department of Internal Medicine and Department of Rheumatology, Timișoara, Romania, during the time period between January 2017 and December 2022, on a group of 26 patients with MCTD and 26 SSc patients. Antinuclear antibodies, anti-U1-RNP, anti-Scl 70, anti-centromere, anti-cardiolipin antibodies (aCL) (IgM, IgG), anti-β2-glycoprotein I (aβ2GPI) (IgM, IgG) antibodies, and lupus anticoagulant (LAC) were determined in both the groups. PAH was evaluated through cardiac ultrasonography, determining the sPAP (systolic pulmonary artery pressure). Nailfold capillaroscopy was performed using a USB Digital Microscope and 2.0-megapixel digital camera recording capillaries density, giant capillaries, enlarged capillaries, capillaries hemorrhages, avascular areas, ramified/bushy capillaries scores. Data were recorded and presented as mean ± standard deviation. Statistical analyses were performed using the Student's t-test, ANOVA test, and Pearson's correlation. Differences were considered statistically significant if p-value < 0.05.
RESULTS: Among the MCTD patients, PAH was identified in 12 patients (46.15%), while among the SSc patients PAH was identified in 14 patients (53.84%). Development of PAH in MCTD patients was associated with lower capillaries density (p-value < 0.00001), higher scores of giant capillaries, ramified/bushy capillaries, and capillary hemorrhages (p-value < 0.00001, for each of them). Anti-U1-RNP, aCL, aβ2GPI antibodies and LAC were also found to be involved in PAH-associated MCTD development. Unlike MCTD patients, SSc patients with PAH presented with lower capillaries density and ramified/bushy capillaries scores (p-value < 0.05).
CONCLUSIONS: The MCTD patients who presented significant NFC abnormalities (especially active and late scleroderma-like capillaroscopic pattern) are prone to PAH development. Capillary density reduction is the most important factor associated with the occurrence of PAH. Differences in NFC findings (especially capillary density and ramified/bushy capillaries) were detected among patients with MCTD and SSc having PAH.
Sham occipital nerve stimulation from activation to 12 weeks post-activation. Active occipital nerve stimulation from 12 weeks post-activation on.
Estramustine phosphate is an anti-mitotic chemotherapeutic drug with proven efficacy against cancer. The invention describes methods which potentiate the therapeutic benefit of intravenous estramustine phosphate. The invention provides for intravenous estramustine phosphate to be administrated at a high dosage exceeding 1300 mg as a single dose. Efficacious enhancement of estramustine phosphate pharmacokinetics is thereby achieved. Further provided, estramustine phosphate may be intravenously administered for use in combinational regimens with other chemotherapeutic agent. The therapeutic advantages achieved using the intravenous estramustine phosphate formulation are applicable to treatment of a variety of cancers including prostate cancer, breast cancer, lung cancer, colorectal cancer, pancreatic cancer, ovarian cancer, melanoma, and other cancers.
With the patient in the prone position the skin is disinfected .Linear USG probe is placed on the spine of the scapula using an in-plane technique and moved medially. The 3rd rib is identified just on the medial scapular border. After visualizing the trapezius, rhomboid major, and serratus posterior superior muscles (from top to bottom) under USG guidance, a 22-G X 80-mm block needle is directed caudally and advanced until it contacted the rib. To confirm and obtain a plane between the serratus posterior superior and intercostal muscles, hydrodissection is performed using 2 ml of isotonic solution. After the needle site is confirmed, 30 ml of 0.25% bupivacaine is injected ; the local anesthetic spread is confirmed by USG.
Patients will drink coconut water for 7 days. After a washout period of 2 weeks, patients will then drink citric soda for 7 days.
Experimental sites designated to receive minimally invasive non-surgical periodontal therapy will undergo careful scaling and root planing under magnification (use of 3.5 X magnification loupes) with mini curettes and using an ultrasonic device with specific thin and delicate tips. These instruments will be carefully inserted through the periodontal pocket of the affected tooth to reach the root surface for debridement. Caution will be taken to preserve the stability of soft tissues.
PROBLEM TO BE SOLVED: To obtain the subject composition capable of improving the stability thereof in a preservation period of a laccase and exhibiting the action of the laccase effectively by containing the laccase and specifying the oxygen concentration of the composition. SOLUTION: This composition for hair dyeing is obtained by containing (A) a color-developing substance, (B) 0.0005-1 wt.%, preferably 0.005-0.5 wt.% laccase as an oxidizing agent and, as necessary, (C) an anti-oxidant, (D) a coupler component, (E) a surfactant, (F) a liquefied petroleum gas, or the like, so as to limit <=0.00015 wt.% oxygen concentration. The component B is an enzyme classified as E. C. 1. 10. 3, and as a representative reaction example, it is known that urushiol is oxidized by a laccase contained in a Japanese lacquer tree liquid to form the Japanese lacquer. The component B presents widely in many plants and microorganisms in addition to Japanese lacquer tree and is an enzyme catalyzing the oxidation reaction of aromatic compounds.
This group will have 15 women in puerperium and will be realize an interview to avalide the cesarean discomforts in immediate puerperium. These dates will be use for elaborate the orientations guide.
BACKGROUND: The prevalence of sleep disorders among medical students was high during the COVID-19 pandemic. However, fewer studies have been conducted on sleep disorders among medical students after the COVID-19 pandemic. This study investigated the prevalence and factors influencing sleep disorders among Chinese medical students after COVID-19.
METHODS: A total of 1,194 Chinese medical students were included in this study from 9th to 12th July 2023. We used the Self-administered Chinese scale to collect the demographic characteristics. In addition, we used the Chinese versions of the Self-rating Depression Scale (SDS), the Self-rating Anxiety Scale (SAS), and the Pittsburgh Sleep Quality Index (PSQI) to assess subjects' depression, anxiety, and sleep disorders, respectively. The chi-square test and binary logistic regression were used to identify factors influencing sleep disorders. The receiver operating characteristic (ROC) curve was utilized to assess the predictive value of relevant variables for sleep disorders.
RESULTS: We found the prevalence of sleep disorders among medical students after COVID-19 was 82.3%. According to logistic regression results, medical students with depression were 1.151 times more likely to have sleep disorders than those without depression (OR = 1.151, 95% CI 1.114 to 1.188). Doctoral students were 1.908 times more likely to have sleep disorders than graduate and undergraduate students (OR = 1.908, 95% CI 1.264 to 2.880).
CONCLUSION: The prevalence of sleep disorders among medical students is high after COVID-19. In addition, high academic levels and depression are risk factors for sleep disorders. Therefore, medical colleges and administrators should pay more attention to sleep disorders in medical students after the COVID-19 pandemic. Regular assessment of sleep disorders and depression is essential.
The invention relates to an intelligent flavor blending device capable of being connected to the Internet. The device comprises a base, a top cover and a control module. The base is provided with a sampling region and an adjusting region. A positioning module is movably arranged on the top cover. A multi-pipe sampling module is arranged below the positioning module and comprises a dropper inserting groove and a plurality of droppers placed in the dropper inserting groove. Each dropper comprises an outer tube and a sampling piston arranged in the outer tube. The inner diameters of the droppers in different sets are different. Piston driving modules are arranged corresponding to the sampling pistons. The positioning module and the piston driving modules are connected with a control module. An Internet access module and a storage device are further connected to the control module. Through the adoption of the device, on one hand, essential oil finished products in different proportions can be accurately blended; meanwhile formulae are shared or acquired through the mobile Internet, and interaction with other users and formula updating can be achieved by means of the flavor blending device.
Chronic obstructive pulmonary disease (COPD) has been associated with alterations in the brain cortical structure. Nonetheless, the causality between COPD and brain cortical structure has not been determined. In the present study, we used Mendelian randomization (MR) analysis to explore the causal effects of genetic predicated COPD on brain cortical structure, namely cortical surface area (SA) and cortical thickness (TH). Genetic association summary data for COPD were obtained from the FinnGen consortium (N = 358,369; Ncase = 20,066). PRISm summary genetic data were retrieved from a case-control GWAS conducted in the UK Biobank (N = 296,282). Lung function indices, including forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and FEV1/FVC, were extracted from a meta-analysis of the UK Biobank and SpiroMeta consortium (N = 400,102). Brain cortical structure data were obtained from the ENIGMA consortium (N = 51,665). Inverse-variance weighted (IVW) method was used as the primary analysis, and a series of sensitivity tests were exploited to evaluate the heterogeneity and pleiotropy of our results. The results identified potential causal effects of COPD on several brain cortical specifications, including pars orbitalis, cuneus and inferior parietal gyrus. Furthermore, genetic predicated lung function index (FEV1, FVC and FEV1/FVC), as well as PRISm, also has causal effects on brain cortical structure. According to our results, a total of 15 functional specifications were influenced by lung function index and PRISm. These findings contribute to understanding the causal effects of COPD and lung function to brain cortical structure.
125,618. Vickers, Ltd., Elia, G. E., and North, T. K. Sept. 13, 1916. Mines, marine. - Relates to submarine mines provided with extensible arms which, on impact with a ship, rotate relatively to the mine, causing the mine to be released and to rise by its buoyancy while the tension in the mooring-cable first cocks and then releases a spring striker, firing the mine. According to the invention, a " driving " member 1, Fig. 1, carrying the arm 10 is mounted in a bearing 2 m the bottom of the mine 4, and is attached at one end to the rod 6 of a spring striker 54, and at the other end to the @oring- cable by means of a shackle 8. The driving- member 1 is locked to a ring 22 against rotation by keys 23, and against longitudinal motion by radial bolts 11, Fig. 3, which are confined within the ring 22 by rollers 16 in the surrounding casing. The ring 22 is itself mounted without longitudinal freedom in the surrounding casing, and is locked against rotation by pins 26 in engagement with radial slots 25 in yokes 21, which are pressed by springs 28 against rollers 18: the yokes are indented to fit the surfaces of the rollers, forming a spring grip which yields only to a strong force. The casing surrounding these parts comprises an upper part 32 brazed to the mine and a cup-shaped lower part 33 secured to the upper part by bolts 35, a flanged steel ring 36<1> and a leather washer 36 being interposed to make the casing watertight. A disk 45 is secured to the top of the lower part by screws and is formed with a boss 47 which screws into the striker casing 50. The joint between the driving-member 1 and its bearing 2 on the lower part of the casing is made water-tight by an extensible corrugated lead tube 38, which is clamped to the bearing 2 and to a boss 37 on the driving-member by wires 39, Fig. 6, threaded through a block 41 and tightened by nuts 44. When the driving-member 1 is rotated relatively to the mine on impact of the mine with a ship, the bolts 11 are released from the rollers 16 and are wedged aside by the driving-member 1 as the mine rises by its buoyancy. The rising mine then compresses the striker spring until radial bolts 57 are wedged into a recess 58, releasing the striker 54 from the rod 6 and thus firing the mine. The arm 10 is passed transversely through the driving- member 1 and is then locked thereto by a pin 60. The outer part of the arm 10 is extended by a spring 65 when released from a gripping-device 62, 63, Fig. 5, by the dissolution of a plug 67. A screw 66 is screwed in the jaw 63 over the plug 67 to ensure that the jaw 63 shall grip the arm 10 tightly against the cradle 62 irrespective of the size of the plug 67.
NEW MATERIAL:AC5Y expressed by the formula. USE:An antitumor agent or antimicrobial agent, having antitumor activity and antimicrobial activity, and exhibiting antimicrobial activity particularly against Penicillium chrysogenum, and usable as an antibiotic effective for infectious diseases caused thereby. PREPARATION:A strain No.23-41 (FERM-P No.7771) belonging to Streptomyces capoamus is cultivated in a culture medium, e.g. glucose, malt extract or yeast extract, etc. preferably at 25-30 deg.C by aerobic liquid submerged culture method, etc., and the resultant culture filtrate is extracted with a water-immiscible solvent for the AC5Y, e.g. ethyl acetate, etc. to collect the aimed AC5Y from the culture.
We report an unexpected death of a 22-year-old primigravida who was admitted to the hospital with sudden abdominal pain two days before a scheduled delivery. During an emergency caesarean section due to intrauterine asphyxia, intraabdominal bleeding was observed with no apparent source of bleeding. Newly formed blood clots in the subdiaphragmatic space and arterial bleeding near the splenic hilum required a surgery on the next day. Hemorrhagic shock led to multiple organ failure on the fourth day of admission. The autopsy revealed ruptured splenic artery at the pancreatic tail and near the splenic hilum. Microscopically, different stages of segmental arterial mediolysis were observed in partially thinned and aneurysmatic artery.
Purpose: To perform longitudinal studies of clinical outcomes and personal perspectives following utilization of PGT.

Background: Preimplantation Genetic Testing (PGT) is a commercially available adjunct to in vitro fertilization (IVF) and is now performed in over 40% of treatment cycles in the United Sates (Society for Assisted Reproductive Technology Annual Report, 2018). Several clinical genetics entities offer PGT services, including Genomic Prediction Clinical Laboratory (CLIA# 31D2152380, CAP# 8488628). It is common practice to perform interviews with, and record reviews of patients following clinical interventions. Results may provide instrumental information for the scientific and medical community to improve clinical care. We would like to review medical records in order to recruit patients to participate in longitudinal studies of clinical outcomes and personal perspectives following utilization of PGT.

Study Design and Methods: Patients indicating willingness to participate in research during informed consent to perform PGT will be eligible for inclusion. Patients who opted out of participating in research during informed consent to perform PGT will be ineligible for inclusion. Clinical PGT consent forms will be reviewed to identify patients that indicated willingness to participate in research. Eligible patients will be counseled on the study and consented for participation by a licensed genetic counselor. A total of 10,000 patients will be recruited. Following patient recruitment and informed consent, patient records and results of patient interviews may be used for publication in peer-reviewed scientific journals, presentation at scientific conferences or company meetings. As it is in standard practice, all external communication of results will maintain de-identification of all protected health information of all subjects (HIPAA guidelines). A licensed genetic counselor will conduct a recorded interview. Patient PGT, family history, and ethnicity data and information may be included in cohort analyses.
The efficacy of AYVAKIT was demonstrated in NAVIGATOR (NCT02508532), a multi-center, single-arm, open-label clinical trial. Eligible patients were required to have a confirmed diagnosis of GIST and an ECOG performance status (PS) of 0 to 2. Patients received AYVAKIT 300 mg or 400 mg (1.33 times the recommended dose) orally once daily until disease progression or unacceptable toxicity. The trial initially enrolled patients at a starting dose of 400 mg, which was later reduced to the recommended dose of 300 mg due to toxicity. As there was no apparent difference in overall response rate (ORR) between patients who received 300 mg daily compared to those who received 400 mg daily, these patients were pooled for the efficacy evaluation. The major efficacy outcome measure was ORR based on disease assessment by independent radiological review using modified RECIST v1.1 criteria, in which lymph nodes and bone lesions were not target lesions and progressively growing new tumor nodules within a pre-existing tumor mass was progression. An additional efficacy outcome measure was duration of response (DOR).

Patients with GIST Harboring a PDGFRA Exon 18 Mutation

Patients with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation were identified by local or central assessment using a PCR- or NGS-based assay. The assessment of efficacy was based on a total of 43 patients, including 38 patients with PDGFRA D842V mutations. The median duration of follow up for patients with PDGFRA exon 18 mutations was 10.6 months (range: 0.3 to 24.9 months).

The study population characteristics were median age of 64 years (range: 29 to 90 years), 67% were male, 67% were White, 93% had an ECOG PS of 0-1, 98% had metastatic disease, 53% had largest target lesion >5 cm, and 86% had prior surgical resection. The median number of prior kinase inhibitors was 1 (range: 0 to 5).

Efficacy results in patients with GIST harboring PDGFRA exon 18 mutations including the subgroup of patients with PDGFRA D842V mutations enrolled in NAVIGATOR are summarized in Table 11.
MYDAYIS has a high potential for abuse and misuse which can lead to the development of a substance use disorder, including addiction [see Warnings and Precautions (5.1)]. MYDAYIS can be diverted for non-medical use into illicit channels or distribution.

Abuse is the intentional non-therapeutic use of a drug, even once, to achieve a desired psychological or physiological effect. Misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a healthcare provider or for whom it was not prescribed. Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use (e.g., continuing drug use despite harmful consequences, giving a higher priority to drug use than other activities and obligations), and possible tolerance or physical dependence.

Misuse and abuse of amphetamine may cause increased heart rate, respiratory rate, or blood pressure; sweating; dilated pupils; hyperactivity; restlessness; insomnia; decreased appetite; loss of coordination; tremors; flushed skin; vomiting; and/or abdominal pain. Anxiety, psychosis, hostility, aggression, and suicidal or homicidal ideation have also been observed with CNS stimulants abuse and/or misuse. Misuse and abuse of CNS stimulants, including MYDAYIS, can result in overdose and death [see Overdosage (10)], and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.
This Phase 2, multicenter, open-label single-arm segment (2A) followed by a double-blind, randomized, active-controlled segment (2B) is designed to evaluate ACX-362E in the treatment of CDI. Segment 2A of this trial was an open-label study of up to 20 patients at 6 study centers and was terminated early at 10 patients based on the protocol-specified Trial Oversight Committee's assessment of the compelling efficacy and safety data. Patients were treated with 450 mg of oral ibezapolstat bid for 10 days. In segment 2A all (10 of 10) patients were cured of CDI at end of treatment and all (10 of 10) were sustained clinical cures 30 days after EOT. Ibezapolstat was well tolerated with no reported SAEs. The trial will advance to Segment 2B which is a double-blind comparison of ibezapolstat to the standard of care, oral vancomycin, in approximately 64 subjects (1-1 randomization) at up to approximately 15 sites.

Subjects will be evaluated for cure, safety, and tolerability. All subjects in both segments will have stool samples tested for microbiome profiles. Pharmacokinetic (PK) testing for systemic exposure will be performed on blood samples. Stool samples will be tested for study drug concentration.
Disclosed is a health related method and apparatus for collecting, collating and filtering information, related to specific individuals and/or their families, obtained from purchases made in conjunction with product source shopper loyalty program cards. Authorization for the collection of the information is made in advance of the collection. An analysis of the collected information is used to provide a health related report, specific to a given individual or family, of deficiencies in the recipient's diet and/or medicine. The total collected information may be subdivided into groups of entities having certain commonalities. Accompanying the report, coupons are provided for products that are known to be beneficial to correcting health related deficiencies and attributes, for a commonality group of consumers, as well as health related educational material for helping the recipient ascertain which health related products should next be purchased. In addition, the material may provide educational material to inform the consumer about health in general, healthy food preparation recipes, the advertised products specifically, the health benefits relating to types of advertised products and detailed nutritional value listing of advertised products as may be found of the product packages.
PCT No. PCT/SE93/00503 Sec. 371 Date Feb. 17, 1994 Sec. 102(e) Date Feb. 17, 1994 PCT Filed Jun. 7, 1993 PCT Pub. No. WO93/25227 PCT Pub. Date Dec. 23, 1993.The present invention relates to the use of iGF-II or effective analogues thereof for the manufacture of a medicament for prevention or treatment of nutritional or gastrointestinal disorders and for promoting human or animal neonatal growth. It also relates to composition comprising exogenous human or animal IGF-II or effective analogues thereof in a therapeutically effective amount together with a pharmaceutically acceptable carrier or diluent or foodstuff, preferably in admixture with artificial or natural milk or colostrum. The invention may be applied both in man and in animals.